Moderna starts testing its vaccine among teens

5:15 PM 10 December 2020
Moderna (MRNA.US) announced today that it has begun a phase 2/3 clinical trial designed to position its COVID-19 vaccine for use in children aged 12 to less than 18 before the start of the 2021-22 school year. The drugmaker  has dosed the first participant in a study expected to enroll 3,000 healthy people. The study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA). "Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year," said Chief Executive Officer Stéphane Bancel. Meanwhile US FDA will meet on December 17th to discuss whether to recommend the use of Moderna's vaccine.
Yesterday Moderna received a downgrade from Needham from ‘Buy’ to ‘Hold’ rating. Analysts believe that Moderna's stock is fully valued after capturing an eightfold gain this year.
Moderna (MRNA.US) stock is testing major support at $150.00 which coincides with 50 SMA (green line) and upward trendline. As long as the price sits above it, the continuation of a upward trend looks probable. The nearest key resistance lies at the $178.68 level. However if sellers will manage to break below the support zone, a downward impulse towards $129.12 could be launched. Source: xStation5
Share:
Back

Join over 1 600 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits